RAD51 and neoplasm: The present study aims to assess RAD51 protein expression in tumor tissues of patients with advanced HGSOC, analyze its correlation with NACT chemotherapy sensitivity and prognosis, and evaluate the potential of RAD51 as a predictive marker for chemotherapy sensitivity in NACT.